CA2876982A1 - Use of ferric citrate in the treatment of chronic kidney disease patients - Google Patents

Use of ferric citrate in the treatment of chronic kidney disease patients Download PDF

Info

Publication number
CA2876982A1
CA2876982A1 CA2876982A CA2876982A CA2876982A1 CA 2876982 A1 CA2876982 A1 CA 2876982A1 CA 2876982 A CA2876982 A CA 2876982A CA 2876982 A CA2876982 A CA 2876982A CA 2876982 A1 CA2876982 A1 CA 2876982A1
Authority
CA
Canada
Prior art keywords
ferric citrate
iron
patient
mean
ckd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2876982A
Other languages
English (en)
French (fr)
Inventor
Enrique Poradosu
Ron BENTSUR
James F. Oliviero, Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keryx Biopharmaceuticals Inc
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of CA2876982A1 publication Critical patent/CA2876982A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/295Iron group metal compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2876982A 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients Abandoned CA2876982A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261662565P 2012-06-21 2012-06-21
US61/662,565 2012-06-21
US201361757229P 2013-01-28 2013-01-28
US61/757,229 2013-01-28
US201361800618P 2013-03-15 2013-03-15
US201361801050P 2013-03-15 2013-03-15
US61/801,050 2013-03-15
US61/800,618 2013-03-15
PCT/US2013/047134 WO2013192565A2 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients

Publications (1)

Publication Number Publication Date
CA2876982A1 true CA2876982A1 (en) 2013-12-27

Family

ID=49769729

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2876982A Abandoned CA2876982A1 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients

Country Status (19)

Country Link
US (3) US20130345303A1 (enExample)
EP (3) EP2863906B1 (enExample)
JP (4) JP2015535209A (enExample)
KR (2) KR20200103855A (enExample)
CN (2) CN113244209A (enExample)
AU (2) AU2013278000A1 (enExample)
BR (1) BR112014032049A2 (enExample)
CA (1) CA2876982A1 (enExample)
DK (1) DK3730136T3 (enExample)
EA (1) EA201590062A1 (enExample)
ES (2) ES2970050T3 (enExample)
FR (1) FR25C1043I1 (enExample)
HK (1) HK1214503A1 (enExample)
IL (1) IL236356A0 (enExample)
MX (1) MX2014015615A (enExample)
NO (1) NO2025048I1 (enExample)
PL (1) PL3730136T3 (enExample)
SG (2) SG10201805177PA (enExample)
WO (1) WO2013192565A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140016438A (ko) 2009-07-21 2014-02-07 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
TWI653043B (zh) * 2012-12-20 2019-03-11 瑞士商伊蘭科動物健康公司 新用途
RU2728778C2 (ru) 2013-06-05 2020-07-31 Трисида, Инк. Протон-связывающие полимеры для перорального введения
ES2856261T3 (es) * 2013-10-01 2021-09-27 Fresenius Medical Care Deutschland Gmbh Método y aparatos para determinar una pérdida diaria de hierro de un paciente
AU2014341975A1 (en) * 2013-11-04 2016-05-19 Keryx Biopharmaceuticals, Inc. Ferric citrate for reducing cardiac failure in chronic kidney disease patients
WO2015110968A1 (en) * 2014-01-23 2015-07-30 Lupin Limited Pharmaceutical grade ferric citrate and method for its production
US10172882B2 (en) 2014-06-22 2019-01-08 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
KR102625115B1 (ko) 2014-12-10 2024-01-12 트리시다, 인크. 경구 투여용 양성자-결합 폴리머
JP2018507260A (ja) * 2015-03-04 2018-03-15 ケリク バイオファーマシューティカルス, インコーポレーテッド 鉄欠乏性貧血の治療におけるクエン酸第二鉄の使用
CN104688706B (zh) * 2015-04-01 2017-07-14 成都欣捷高新技术开发有限公司 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法
WO2016162794A1 (en) * 2015-04-08 2016-10-13 Leiutis Pharmaceuticals Pvt Ltd Pharmaceutical compositions of ferric citrate
WO2016162888A1 (en) * 2015-04-09 2016-10-13 Actavis Group Ptc Ehf. Process for preparing pharmaceutical grade ferric citrate
IL308673A (en) 2016-05-06 2024-01-01 Tricida Inc Compositions for and method of treating acid-base disorders
WO2019059172A1 (ja) 2017-09-19 2019-03-28 日本たばこ産業株式会社 過多月経患者及び/又は過多月経を伴う婦人科疾患を有する患者における鉄欠乏性貧血の予防及び/又は治療におけるクエン酸第二鉄の使用
SG11202003451UA (en) 2017-11-03 2020-05-28 Tricida Inc Compositions for and method of treating acid-base disorders
WO2019236639A1 (en) * 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
CN113613662A (zh) 2018-10-29 2021-11-05 法码科思莫斯控股有限公司 用羧基麦芽糖铁治疗铁缺乏
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN117999069A (zh) 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物
CN115024495B (zh) * 2022-06-27 2024-03-22 北京金康普食品科技有限公司 改善肾病患者钙磷代谢的营养组合物及其应用
WO2025181559A1 (en) * 2024-02-29 2025-09-04 Sloiron, Inc. Methods for determining the amount of encapsulated and free iron in a sample

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000067929A (ko) * 1996-07-19 2000-11-25 나가타 코이치 고인혈증 치료제
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
CN1600302A (zh) * 2003-09-22 2005-03-30 宝龄富锦生技股份有限公司 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
KR20080037083A (ko) 2005-08-18 2008-04-29 글로보아시아 엘엘씨 약학용 등급의 유기 철 화합물, 그 용도 및 이의 제조 방법
KR20180077337A (ko) * 2006-01-06 2018-07-06 루이트폴드 파머수티컬스, 인코퍼레이티드 철을 투여하기 위한 방법 및 조성물
CN105055446B (zh) * 2006-01-30 2022-06-03 宝龄富锦生技股份有限公司 逆转、防止、延迟或稳定软组织钙化的方法
KR20140016438A (ko) 2009-07-21 2014-02-07 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태

Also Published As

Publication number Publication date
FR25C1043I1 (fr) 2026-01-02
JP2018138562A (ja) 2018-09-06
SG10201805177PA (en) 2018-07-30
MX2014015615A (es) 2015-03-20
EP2863906B1 (en) 2020-03-18
EA201590062A1 (ru) 2016-02-29
KR20150036131A (ko) 2015-04-07
EP2863906A2 (en) 2015-04-29
EP3730136A1 (en) 2020-10-28
NO2025048I1 (no) 2025-11-06
SG11201408521WA (en) 2015-01-29
AU2018203205A1 (en) 2018-05-31
BR112014032049A2 (pt) 2017-07-25
EP4335436A3 (en) 2024-05-15
US20140234416A1 (en) 2014-08-21
US20150079168A1 (en) 2015-03-19
ES2796254T3 (es) 2020-11-26
HK1210013A1 (en) 2016-04-15
WO2013192565A2 (en) 2013-12-27
PL3730136T3 (pl) 2024-03-25
JP2022070945A (ja) 2022-05-13
EP3730136B1 (en) 2023-12-27
ES2970050T3 (es) 2024-05-24
CN113244209A (zh) 2021-08-13
DK3730136T3 (da) 2024-01-22
US20130345303A1 (en) 2013-12-26
KR102150135B1 (ko) 2020-08-31
JP2015535209A (ja) 2015-12-10
JP2020100638A (ja) 2020-07-02
EP4335436A2 (en) 2024-03-13
WO2013192565A3 (en) 2015-10-15
AU2018203205B2 (en) 2020-03-12
HK1214503A1 (zh) 2016-07-29
AU2013278000A1 (en) 2015-01-22
KR20200103855A (ko) 2020-09-02
IL236356A0 (en) 2015-02-26
CN104884055A (zh) 2015-09-02

Similar Documents

Publication Publication Date Title
AU2018203205B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
JP6828100B2 (ja) 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
TWI812580B (zh) 檸檬酸鐵用於治療缺鐵性貧血之用途
US20240041816A1 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
US20190269645A1 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
HK1210013B (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524A (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180613

FZDE Discontinued

Effective date: 20220419

FZDE Discontinued

Effective date: 20220419

FZDE Discontinued

Effective date: 20220419